share_log

Chardan Capital Reiterates Buy on Gain Therapeutics, Maintains $6 Price Target

Benzinga ·  Mar 27 04:38

Chardan Capital analyst Keay Nakae reiterates Gain Therapeutics (NASDAQ:GANX) with a Buy and maintains $6 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment